DIRS.INFO The most relevant business & tech news

☆ Goldman Sachs says the S&P 500 will remain flat through 2023. Here's their 5-step playbook for finding returns — and avoiding crippling losses — next year.
▼ + stars: | 2022-11-23 | by ( William Edwards | ) www.businessinsider.com time to read: +4 min

Third, long-duration stocks that are unprofitable — typically these are growth stocks found in the tech sector — should be avoided, Kostin said. Fourth, Kostin likes stocks that have growing profit margins despite the tightening economic conditions. He shared a list of stocks with the most resilient profit margins over the last few year, and which are expected to grow margins next year. And finally, Kostin recommended avoiding stocks whose profit margin growth in recent years may have been due to a decrease in expenses as opposed to an increase in sales. Rising or normalizing expenses for these companies could chip away at profit margins.

☆ Credit Suisse touts drug stocks as a top place to be. These are our 2 favorites
▼ + stars: | 2022-11-18 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Like the Club, Credit Suisse holds a positive view on Mounjaro — the company's diabetes drug that's shown immense promise as an obesity treatment, too — and Lilly's latest experimental Alzheimer's drug ahead of a pivotal data release expected next year. However, we differ on J & J, which will soon break itself up. The remaining J & J will be its current pharmaceutical and medical technologies divisions. Credit Suisse rates J & J as neutral with a $170 price target, which is nearly 4% below where the stock closed Thursday. A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

☆ Here are the 10 stocks we consider our core holdings in the Club portfolio — and why
▼ + stars: | 2022-11-17 | by ( Jeff Marks | ) www.cnbc.com time to read: +12 min

At the Investing Club, we generally try to keep our portfolio to around 30 stocks, give or take a few. In light of Thursday's "Monthly Meeting," we wanted to identify what we consider our 10 core holdings of the 32. We may consider a stock a core holding today but that could change three months from now. Management sees its post-separation core business growing revenues at a high single-digit clip and earnings-per-share increasing in the double digits. The stock provides a stellar dividend yield of nearly 3.5%, and the bank has plenty of excess capital to repurchase stock quarter after quarter, while other banks have paused their buybacks.

☆ Here's our November rapid-fire update on the stocks in Cramer's Charitable Trust portfolio
▼ + stars: | 2022-11-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

We think the stock has been hurt by a recent update to the company's reserve quantity. While we're big fans of the company's recent corporate governance cleanup , and we expect some near-term selling pressure associated with those efforts. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Fake account shows 'challenges' with Twitter - Lilly CEO
▼ + stars: | 2022-11-16 | by ( ) www.reuters.com time to read: +1 min

[1/3] FILE PHOTO: Twitter app logo is seen in this illustration taken, August 22, 2022. REUTERS/Dado Ruvic/Illustration/File Photo/File PhotoNov 16 (Reuters) - Eli Lilly & Co (LLY.N) Chief Executive Officer Dave Ricks said on Wednesday that the recent imposter Twitter account incident "demonstrates some of the challenges" on the social media platform. Speaking at the STAT Summit 2022, Ricks described the incident as "disappointing" and said that the apology which followed from Lilly did not "happen quickly enough". The drugmaker had issued an apology from its official Twitter account, @LillyPad, after an imposter Twitter account with the handle @EliLillyandCo tweeted that insulin would be free, amid political backlash and scrutiny into high medicine costs. Reporting by Bhanvi Satija in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

☆ Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
▼ + stars: | 2022-11-16 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. The recommendations are a draft, NICE said, and until final guidance is published, access to COVID-19 medicines will continue as is. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (GILD.O) hospital-administered antiviral remdesivir are effective at treating COVID-19. It also recommended against three other COVID treatments, including GSK (GSK.L) and partner Vir Biotechnology's (VIR.O) sotrovimab, an antibody therapy that the World Health Organization recommended against in September. One expert said that some of the COVID treatments NICE recommended against are an important part of the British government's current strategy.

The main active ingredient in Ozempic is semaglutide, which is also the key ingredient in Novo's obesity drug Wegovy. Several less efficacious obesity drugs from multiple drugmakers have previously been approved, but bungled launches and serious side effects led to tepid sales and even some market withdrawals. Novo faces looming competition from Eli Lilly (LLY.N), whose weekly injection Mounjaro won U.S. approval for type 2 diabetes in May and is under fast-track review as a weight-loss drug. Amgen (AMGN.O) also has an early-stage, once-monthly obesity drug that is being keenly watched. Elon Musk, the world's richest person and now Twitter owner, has offered his own endorsement of the weight-loss benefits of semaglutide on the social media website.

☆ What the Club is watching Tuesday — more cooler inflation, Dow stock earnings, price target hikes
▼ + stars: | 2022-11-15 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +4 min

Truist raises price target on Eli Lilly (LLY) to $421 per share from $400. Club holding Procter & Gamble (PG) price target cut to $130 per share from $140 at Credit Suisse. Mizuho cuts price target on Club holding Salesforce (CRM) to $225 per share from $235. Amazon initiated with an outperform (buy) rating at MoffettNathanson, with a price target of $118 per share. Bank of America double upgrades Netflix (NFLX) to a buy rating from a sell, with a price target of $370 per share.

The comments follow a softer-than-expected inflation report last week, which had buoyed hopes that the Fed could scale back its hefty interest rate hikes and helped drive a euphoric market rally. The S&P 500 in the previous session logged its biggest weekly percentage gain in about five months, while the tech-heavy Nasdaq (.IXIC) notched its best week since March. "The market is expecting the Fed to continue its hawkish rhetoric on rates. ET, the S&P 500 (.SPX) was down 17.25 points, or 0.43%, at 3,975.68, and the Nasdaq Composite (.IXIC) was down 115.13 points, or 1.02%, at 11,208.20. The S&P 500 information technology sector (.SPLRCT) was down 1.2% and among the leading sectoral decliners on the benchmark index.

The comments follow a softer-than-expected inflation report last week, which had buoyed hopes that price pressures were easing and the Fed could scale back its hefty interest rate hikes. "The market is expecting the Fed to continue its hawkish rhetoric on rates," said Peter Cardillo, chief market economist at Spartan Capital Securities. Once they (Fed) raise rates at 50 (bps), there's a possibility that they might indicate slower rates." Traders now expect the Fed to hike interest rates in December by a half point, and expect terminal rate in the range of 4.75%-5.0% next year. ET, Dow e-minis were down 50 points, or 0.15%, S&P 500 e-minis were down 11.5 points, or 0.29%, and Nasdaq 100 e-minis were down 62 points, or 0.52%.

☆ What Cramer is watching Monday — two AMD upgrades, Microsoft hesitancy, Alzheimer's results
▼ + stars: | 2022-11-14 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Baird upgrades Advance Micro Devices (AMD) to outperform from neutral (buy from hold) and raises price target to $100 per share from $65. UBS goes to a buy from neutral as well and raises price target to $95 from $75. Oppenheimer cuts price target on Club holding Nvidia (NVDA) to $225 per share from $250. Credit Suisse analyst Scott Deuschle assumes coverage on Honeywell (HON) with a neutral rating and a $202-per-share price target. Good for Club holding Eli Lily (LLY) and Biogen (BIIB), which are each working on separate experiment treatments for the disease.

☆ Stocks making the biggest moves in the premarket: Hasbro, Oatly, Advanced Micro Devices and more
▼ + stars: | 2022-11-14 | by ( Peter Schacknow | ) www.cnbc.com time to read: +2 min

Advanced Micro Devices (AMD) – The chip maker's stock rose 3.2% in the premarket after receiving upgrades at both Baird and UBS. Amazon.com (AMZN) – Amazon fell 1.7% in premarket trading after Bank of America removed the stock from its "US 1" list, although it maintained a "buy" rating. Teva Pharmaceutical (TEVA) – Teva was downgraded to "underweight" from "neutral" at J.P. Morgan Securities, which cited continuing growth challenges for the drugmaker. Teva fell 2.3% in premarket action. Lilly added 1.5% in premarket trading, while Biogen rallied 5.8%.

☆ Musk halts Twitter's coveted blue check amid proliferation of imposters
▼ + stars: | 2022-11-12 | by ( Nivedita Balu | ) www.reuters.com time to read: +3 min

The coveted blue check mark was previously reserved for verified accounts of politicians, famous personalities, journalists and other public figures. The flip-flop is part of a chaotic two weeks at Twitter since Musk completed his $44 billion acquisition. Musk has fired nearly half of Twitter's workforce, removed its board and senior executives, and raised the prospect of Twitter's bankruptcy. A number of misleading tweets about Tesla from a verified account with the same profile picture as the company's official account were also being circulated on the platform. In response, the billionaire said on Wednesday he aimed to turn Twitter into a force for truth and stop fake accounts.

☆ After this week's big market rally, here's a rapid-fire update on all 32 stocks in our portfolio
▼ + stars: | 2022-11-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +6 min

Cisco Systems (CSCO): It reports next week and we think it should deliver a decent quarter as it converts its backlog into revenue. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

☆ Twitter gives big advertisers the excuse they need
▼ + stars: | 2022-11-11 | by ( ) www.reuters.com time to read: +2 min

NEW YORK, Nov 11 (Reuters Breakingviews) - Twitter’s new owner Elon Musk is making it too easy to hit the pause on ad spending. loadingSocial media companies are no stranger to ad boycotts. That’s because Facebook and Instagram rely more on small business advertising, which is a diverse scattered group. Twitter reaps almost all its revenue from big brands, and those big advertisers are already looking for an excuse to put the brakes on spending. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

☆ 3 takeaways from our daily meeting: Tech stocks soar, Constellation reclassification, bullish on TJX
▼ + stars: | 2022-11-10 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Tech stocks soar STZ reclassification Bullish on TJX 1. Tech stocks soar on CPI data Tech stocks rallied Thursday along with the broader market on the back of fresh data showing inflation cooled in October , with the consumer price index (CPI) rising less than expected, according to the Bureau of Labor Statistics. Bullish on TJX Off-price retail operator TJX Companies (TJX) is benefiting from October's CPI report, which showed a decrease in apparel prices. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ We're increasing price targets on 3 of our stocks, including 2 crushing the boarder market
▼ + stars: | 2022-11-08 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Following our price target changes on eight Club holdings last month, we're updating three more Tuesday to reflect their recent quarterly earnings reports and outlooks. It's also worth noting that we have not adjusted our Lilly price target since competitor Biogen (BIIB) reported positive topline results from a study to treat early Alzheimer's. Halliburton (HAL): Club price target increasing to $44 per share from $40 This update comes about two weeks after the oilfield services provider reported a stronger-than-expected third quarter . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Eli Lilly says some staff want to leave Indiana because of abortion ban, Financial Times reports
▼ + stars: | 2022-11-06 | by ( ) www.reuters.com time to read: +1 min

Nov 6 (Reuters) - Some Eli Lilly and Co (LLY.N) employees have requested transfers from the drugmaker's Indiana operations after the U.S. state's lawmakers approved a bill that would ban most abortions there, the Financial Times reported on Sunday. Some staff had asked to relocate outside the state even though an Indiana judge has temporarily halted the ban, the Indiana-based pharmaceutical firm's chief executive David Ricks told the newspaper in an interview. His comments come after the Republican-controlled Indiana Senate passed a law in August banning most abortions. An Indiana judge blocked the state in September from enforcing the new law while Planned Parenthood and other healthcare providers challenge it in court. Eli Lilly did not provide details on how many staff have asked to move from Indiana, the FT said.

☆ Eli Lilly says some staff want to leave Indiana because of abortion ban - FT
▼ + stars: | 2022-11-06 | by ( ) www.reuters.com time to read: +1 min

Nov 6 (Reuters) - Some Eli Lilly and Co (LLY.N) employees have requested transfers from the drugmaker's Indiana operations after the U.S. state's lawmakers approved a bill that would ban most abortions there, the Financial Times reported on Sunday. Some staff had asked to relocate outside the state even though an Indiana judge has temporarily halted the ban, the Indiana-based pharmaceutical firm's chief executive David Ricks told the newspaper in an interview. An Indiana judge blocked the state in September from enforcing the new law while Planned Parenthood and other healthcare providers challenge it in court. Ricks said the new restrictions had created challenges for people to come to work in Indiana and that if Eli Lilly wanted to attract and retain the best staff, it had to grow in other locations, the FT said. Eli Lilly did not provide details on how many staff have asked to move from Indiana, the FT said.

☆ Factbox: What are the new BQ.1 and BQ.1.1 coronavirus variants, and why it matters
▼ + stars: | 2022-11-04 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +3 min

The following describes the new coronavirus subvariants and how they may impact people. WHAT ARE BQ.1 AND BQ.1.1? In early July, BA.5 became the dominant subvariant of the coronavirus circulating in the United States, but in October it started giving way to BQ.1 and BQ.1.1. A study of blood from three dozen adults showed the shot increased neutralizing antibodies against the BA.4/BA.5 Omicron subvariants by fourfold compared with the original shot after one month. read moreIt is not yet clear whether that will translate into higher protection against the BQ.1 and BQ.1.1 subvariants, but their close relationship to BA.5 may work in the booster's favor.

☆ COVID variants BQ.1/BQ.1.1 make up 35% of U.S. cases
▼ + stars: | 2022-11-04 | by ( ) www.reuters.com time to read: +2 min

The subvariants made up nearly 9% of total cases in the week of Oct. 15 and their proportion has been rising steadily among circulating cases since then. New variants are monitored closely by regulators and vaccine manufacturers in case they start to evade protection offered by current shots. BQ.1.1 made up nearly 19% of circulating variants and BQ.1 was estimated to make up 16.5% of circulating cases in the week of Nov. 5, the U.S. CDC said on Friday. The BA.5 subvariant, which drove up cases earlier this year, is estimated to make up about 39% of cases, compared with nearly 51% in the week ended Oct. 29. Coronavirus cases saw a small uptick for the week ended Nov. 2, data from CDC showed.

☆ The Fed, earnings, jobs and China: How we think about this week's deluge of data
▼ + stars: | 2022-11-04 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

It is very premature, in my view, to think about or be talking about pausing our rate hikes. The news sent those stocks reliant on China for growth — Starbucks, Estee Lauder and Wynn Resorts, among many others — higher. Or bad news could just be bad news if weak data signals a recession ahead. And good news could be good news: for example, if China reopens and U.S. companies exposed to the region see a boost in demand. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ What Cramer is watching Wednesday — Fed day, AMD signs of life, China hits Estee Lauder
▼ + stars: | 2022-11-02 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

While missing lowered expectations in the third quarter, Club holding AMD did see a year-over-year revenue growth. Club holding Estee Lauder (EL) beats on fiscal first-quarter earnings and matches on revenue. Club holding Devon Energy (DVN): Very strong quarter . Club holding Humana (HUM) sees membership growth. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Organizations: & $

☆ 2 takeaways from our daily meeting: Stocks await Fed decision, Club earnings recap
▼ + stars: | 2022-11-02 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Fed decision ahead Quick takes on Club earnings 1. Fed decision ahead Stocks edged down Wednesday ahead of the Federal Reserve's decision on interest rate increases, set for this afternoon. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Wall St slips as jobs data dents Fed deceleration wish
▼ + stars: | 2022-11-01 | by ( Chuck Mikolajczak | ) www.reuters.com time to read: +3 min

Investors have been paying close attention to labor market data for any signs of weakening in the job market, as decreasing wage pressures and easing demand would help reduce inflation, giving the Fed the ammunition to begin decelerating with a 50-basis-point rate hike in December. "From an employment standpoint things look really robust though, and that is putting some pressure on stocks." According to preliminary data, the S&P 500 (.SPX) lost 16.26 points, or 0.42%, to end at 3,855.79 points, while the Nasdaq Composite (.IXIC) lost 97.62 points, or 0.90%, to 10,889.23. Megacap growth names such as Amazon (AMZN.O) and Apple (AAPL.O), which have struggled since the Fed began raising interest rates, were once again under pressure. Pfizer (PFE.N) rose after the drugmaker raised full-year sales estimates for its COVID-19 vaccine, while Eli Lilly (LLY.N) fell after trimming its profit forecast.

Search resuls for: "LLY"

25 mentions found